LXRX — LEXICON PHARMACEUTICALS INC

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About LEXICON PHARMACEUTICALS INC (LXRX)

LEXICON PHARMACEUTICALS INC (LXRX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $12M. All data sourced from SEC 13F filings.

Tracked investors reporting LXRX

  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    7.8M
    Value
    $12.2M
    % Portfolio
    0.02%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    4.9M
    Value
    $7.7M
    % Portfolio
    0.00%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    1.7M
    Value
    $2.6M
    % Portfolio
    0.00%

Recent activity

  • No recent activity.

Frequently asked questions

How many institutional investors hold LXRX?
3 tracked institutional investors disclosed a position in LXRX (LEXICON PHARMACEUTICALS INC) in their most recent 13F filing.
Who is the largest institutional holder of LXRX?
Steve Cohen, Point72 Asset Management, holds the largest disclosed position in LXRX, valued at $12M.
Did institutional ownership of LXRX increase or decrease?
Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited LXRX.
Where does this LXRX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.